Iloperidone (Fanapt)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
Bipolar Disorder
Schizophrenia
NCT02453893 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2013-11 – 2015-06 · Schizophrenia
What this study did
Phase 2 (4)
Schizophrenia
NCT01623713 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2012-06 – 2013-11 · Schizophrenia, Iloperidone, Efficacy
What this study did
Other / comorbidity
NCT07090161 · Vanda Pharmaceuticals
2025-09-15 – 2026-11 · Hypertension, Uncontrolled Hypertension
What this study did
NCT05344365 · Vanda Pharmaceuticals
2022-06 – 2023-11 · Parkinson Disease Psychosis
What this study did
NCT01917318 · University of Colorado, Denver
2013-07 – 2014-02 · Post Traumatic Stress Disorder
What this study did
Phase 1/2 (1)
Schizophrenia
NCT01348100 · Novartis Pharmaceuticals
2011-04 – 2012-07 · Schizophrenia
What this study did
Phase 1 (7)
Bipolar Disorder
NCT06494397 · Vanda Pharmaceuticals
2024-07-11 – 2024-10-24 · Schizophrenia, Bipolar I Disorder
What this study did
NCT04127058 · Vanda Pharmaceuticals
2019-10-07 – 2019-11-27 · Bipolar I Disorder, Schizophrenia
What this study did
Schizophrenia
NCT04712734 · Vanda Pharmaceuticals
2021-01-13 – 2022-08-30 · Schizophrenia
What this study did
Other / comorbidity
NCT04969211 · Vanda Pharmaceuticals
2021-06-30 – 2021-10-13 · Healthy
What this study did
NCT03420534 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
2017-11-17 – 2018-03-14 · Bioequivalence
What this study did
NCT01495169 · Vanda Pharmaceuticals
2011-10 – 2015-02 · Safety and Tolerability of Iloperidone
What this study did
NCT01529294 · Novartis Pharmaceuticals
2010-08 – 2012-07 · Hepatic Impairment
What this study did
Phase 4 (6)
Bipolar Disorder
NCT05648591 · Vanda Pharmaceuticals
2023-05-24 – 2028-12-31 · Schizophrenia, Bipolar I Disorder
What this study did
NCT02413918 · The University of Texas Health Science Center at San Antonio
2012-04 – 2015-04 · Bipolar Disorder
What this study did
Schizophrenia
NCT01929889 · Northwestern University
2012-04 – 2014-10 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01207414 · Novartis
2010-08 – 2012-01 · Schizophrenia
What this study did
Other / comorbidity
NCT01464229 · Maurizio Fava, MD
2012-04 – 2014-12 · Major Depressive Disorder
What this study did
NCT01920802 · New York State Psychiatric Institute
2012-11 – 2014-09 · Healthy
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 4 (1)
Other / comorbidity
NCT00806234 · Johns Hopkins University
2009-01 – 2014-03 · Psychotic Disorders
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Iloperidone (Fanapt): this drugApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Iloperidone (Fanapt) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Phase 3SchizophreniaRecruiting
Est. primary completion 2027-11 · NCT06961968 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
Phase 4SchizophreniaRecruiting
Est. primary completion 2028-12-31 · NCT05648591 · CT.gov ↗
What to watch

See the full readout calendar ↗